ABVC BIOPHARMA, INC. (American BriVision Holding Corp.) 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 21, 2016, by American BriVision (Holding) Corporation (also referenced as ABVC BIOPHARMA, INC. in metadata). The report details corporate governance actions taken by the Board of Directors on the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Forward Stock Split: The Board approved a forward stock split at a ratio of 1 to 3:141.
- Authorized Share Increase: The number of authorized common shares (par value $0.001) was increased to 360,000,000.
- Shareholder Approval: The amendment to the Articles of Incorporation was approved by a majority of shareholders.
- Effective Date: The changes are expected to be effective on or after April 6, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, market outlook, or specific risk factors. The primary contingency noted is the administrative timeline for the stock split to become effective.
Investor Verification Checklist
- Verify the exact effective date of the stock split (expected on or after April 6, 2016).
- Confirm the interpretation of the split ratio "1 to 3:141" with the company, as this notation is non-standard.
- Check subsequent filings for the updated share count post-split.
- Review the attached Exhibit 4.1 (Amendment to Articles of Incorporation) for legal specifics.